...
首页> 外文期刊>Clinical and Translational Allergy >ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
【24h】

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria

机译:ASSURE-CSU:对有症状的慢性自发性荨麻疹患者疾病负担的真实研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of licensed, recommended doses of modern, second-generation H 1 -antihistamines. So far, the humanistic, societal and economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost-effective manner. Methods ASSURE-CSU is an observational, multicenter study being conducted in the UK, Germany, Canada, France, Italy, Spain, and The Netherlands. The study comprises a retrospective medical chart review in conjunction with patient surveys (including validated tools for assessment of disease impact) and an 8-day patient diary. The primary objectives of the study are to describe patient demographics, medical history, treatments, and healthcare resource utilization based on medical-record data and to assess the impact of disease, healthcare resource utilization, work days missed, and productivity loss based on patient-reported data. Approximately 700 patients (aged ≥18?years) will be enrolled who have CSU/CIU despite currently receiving treatment, and have had persistent symptoms for at least 12?months. Data will be collected retrospectively for the 12?months (±1?month) prior to enrolment wherever possible, and prospectively for the week following enrolment. Discussion ASSURE-CSU will be the first study to examine the economic and humanistic burden of disease in patients diagnosed with CSU/CIU who are symptomatic despite treatment. By combining retrospective evaluation of medical records with prospective patient surveys and 8-day diaries, across seven different countries, the ASSURE-CSU study will contribute to a better understanding and acknowledgement of the burden of disease in patients with symptomatic chronic spontaneous urticaria.
机译:背景慢性自发性荨麻疹(CSU)前身为慢性特发性荨麻疹(CIU)是一种严重而令人痛苦的皮肤病,尽管使用了许可的推荐剂量的现代第二代H 1 -抗组胺药。到目前为止,对CSU / CIU的人文,社会和经济负担尚未得到很好的量化。因此,重要的是,通过确定CSU / CIU的疾病负担和相关的未满足需求,加深我们对CSU / CIU如何影响患者,社会和医疗系统的理解;并以有效和具有成本效益的方式进一步指导新疗法的使用。方法ASSURE-CSU是一项在英国,德国,加拿大,法国,意大利,西班牙和荷兰进行的观察性多中心研究。该研究包括回顾性医学图表审查以及患者调查(包括用于评估疾病影响的经过验证的工具)和8天患者日记。这项研究的主要目标是根据病历数据描述患者的人口统计资料,病史,治疗方法和医疗保健资源利用情况,并根据患者的情况评估疾病,医疗保健资源利用情况,错过的工作日以及生产率下降的影响报告的数据。尽管目前正在接受治疗,仍将招募约700名CSU / CIU且持续症状至少12个月的患者(年龄≥18岁)。在可能的情况下,将在入学前的12个月(±1个月)内回顾性收集数据,并在入学后的一周内对数据进行前瞻性收集。讨论ASSURE-CSU将是第一个检查经诊断为CSU / CIU且尽管有症状但有症状的患者的经济和人道疾病负担的研究。通过将病历的回顾性评估与前瞻性患者调查和8天日记相结合,ASSURE-CSU研究将有助于更好地了解和认识有症状的慢性自发性荨麻疹患者的疾病负担。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号